Community Health Media
Community Health Media
Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts
Be sure to visit the podcast's website and support the creator: communityhealth.media
Author
Community Health Media
Category
Podcast website
Latest episode
Nov 10, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
Dato-DXd Across Breast & Lung Cancer with Drs. Komal Jhaveri, Paolo Tarantino, & Jacob Sands 10.11.2026 36:45
What can breast and lung cancer oncologists learn from each other about TROP2-directed antibody-drug conjugates? Dr. Komal Jhaveri, Dr. Paolo Tarantino, and Dr. Jacob Sands discuss the role of datopotamab deruxtecan (Dato-DXd) across breast and lung cancer, examining clinical trial findings, patient selection, and practical approaches to treatment. Drawing on the TROPION-Breast and TROPION-Lung tr...
SERENA-6: Acting on ESR1 Early with Drs. Jason Mouabbi, Joyce O'Shaughnessy, & Erica Mayer 10.11.2026 35:50
When an ESR1 mutation emerges before radiographic progression, what comes next? Dr. Jason Mouabbi, Dr. Joyce O'Shaughnessy, and Dr. Erica Mayer discuss findings from the SERENA-6 trial, focusing on the use of circulating tumor DNA (ctDNA) to identify emerging ESR1 mutations during first-line endocrine therapy. They examine the progression-free survival benefit observed when patients with newly...
TROP2 ADCs in Breast & Lung Cancer with Drs. Jason Mouabbi, Rebecca Shatsky, & Ryan Gentzler 10.11.2026 46:08
How are TROP2-directed antibody-drug conjugates (ADCs) changing treatment decisions in breast and lung cancer? Dr. Jason Mouabbi is joined by Dr. Rebecca Shatsky and Dr. Ryan Gentzler to discuss the clinical evidence behind datopotamab deruxtecan (Dato-DXd), its role across breast and lung cancer, and the challenges of selecting and sequencing ADC therapies. Drawing on findings from TROPION-Breast...
SERENA-6 and ESR1 Monitoring with Drs. Neil Iyengar, Sarah Sammons, & Tiffany Traina 09.11.2026 37:16
When an ESR1 mutation emerges as a sign of endocrine resistance before radiographic progression, what do we do next? Dr. Neil Iyengar, Dr. Sarah Sammons, and Dr. Tiffany Traina discuss the SERENA-6 trial and what it means for identifying endocrine resistance earlier through circulating tumor DNA (ctDNA) monitoring in HR-positive, HER2-negative metastatic breast cancer. They examine the clinical ev...
ESMO 2026 Roundtable: Sone-Ve, CLARITY-Gastric01 & the Future of CLDN18.2 in Gastric Cancer 09.11.2026 42:53
Could CLDN18.2-targeted antibody-drug conjugates (ADCs) expand treatment options for patients with advanced gastric cancer? Recorded at ESMO 2026 in Madrid, Dr. Yelena Janjigian moderates a roundtable with Dr. Zev Wainberg, Dr. Nataliya Uboha, Dr. Arturo Loaiza-Bonilla, Dr. Sunnie Kim, and Dr. David Zhen on emerging CLDN18.2-targeted therapies in gastric and gastroesophageal junction adenocarcinom...
SERENA-6 in Practice: When to Switch? Drs. Rebecca Shatsky, Melinda Telli, & Anastasia Martynova 09.11.2026 32:23
Should an emerging ESR1 mutation prompt a treatment change before radiographic progression? Dr. Rebecca Shatsky, Dr. Melinda Telli, and Dr. Anastasia Martynova discuss the SERENA-6 trial and how its findings are influencing clinical practice in HR-positive, HER2-negative metastatic breast cancer. They examine the evidence for switching endocrine therapy upon molecular progression with ESR1 mutatio...
ESMO 2026 Roundtable: T-DXd Across the DESTINY-Breast Trials in HER2-Positive Breast Cancer 09.11.2026 1:13:07
Trastuzumab deruxtecan (T-DXd) now spans the HER2-positive breast cancer continuum, from first-line metastatic to early-stage disease. Recorded at ESMO 2026, Dr. Jason Mouabbi moderates a CHM roundtable with Dr. Sara Hurvitz, Dr. Neil Iyengar, Dr. Heather McArthur, Dr. Erika Hamilton, Dr. Paolo Tarantino, and Dr. Tiffany Traina on the clinical implications of DESTINY-Breast09, DESTINY-Breast11, an...
Ataraxis AI in Early Breast Cancer with Drs. Jason Mouabbi & VK Gadi 09.11.2026 20:20
Can AI help distinguish who truly benefits from chemo in early hormone receptor–positive breast cancer? Dr. Jason Mouabbi and Dr. VK Gadi discuss artificial intelligence (AI) in early hormone receptor–positive, HER2-negative breast cancer, focusing on prognostic risk and predicting treatment benefit. Drawing on the TAILORx trial and genomic assays like Oncotype DX, they cover Ataraxis Breast, an A...
Navigating CLL From Frontline to Relapse with Drs. Joanna Rhodes, Prioty Islam & Nicole Lamanna 29.10.2026 52:30
What shapes treatment decisions in chronic lymphocytic leukemia (CLL), from frontline therapy through relapse? Dr. Joanna Rhodes, Dr. Prioty Islam, and Dr. Nicole Lamanna discuss the evolving CLL treatment landscape and share how they approach continuous and fixed-duration therapy, high-risk disease, and toxicity management in everyday practice. They explore how genomic testing, patient preference...
HER2-Low & Ultralow Breast Cancer: Testing & T-DXd with Drs. Neil Iyengar & Sunil Badve 20.10.2026 52:03
Why does accurate HER2 testing matter more than ever for patients with breast cancer? Dr. Neil Iyengar and Dr. Sunil Badve discuss the evolving understanding of HER2-low and HER2-ultralow breast cancer and how advances in pathology and clinical evidence are expanding the population of patients who may be candidates for trastuzumab deruxtecan (T-DXd). Drawing on findings from DESTINY-Breast04 and D...
Special CHM Conversation: Second-Line ER+/HER2- mBC with Drs. Seth Wander & Paolo Tarantino 07.10.2026 21:05
How is the rapidly changing treatment landscape reshaping second-line ER-positive, HER2-negative metastatic breast cancer care? In this Special CHM Conversation, Dr. Seth Wander and Dr. Paolo Tarantino discuss the growing number of endocrine therapy options and how clinicians can navigate increasingly complex treatment decisions. They explore what the newly approved combination of imlunestrant plu...
ESR1-Mutated Breast Cancer: Oral SERDs and Vepdegestrant with Drs. Jason Mouabbi & Erika Hamilton 06.10.2026 42:43
How should clinicians navigate the growing number of treatment options for ESR1-mutated metastatic breast cancer? Dr. Jason Mouabbi and Dr. Erika Hamilton discuss the evolving treatment landscape for hormone receptor-positive, HER2-negative metastatic breast cancer, with a focus on ESR1 mutations, molecular testing, PROTACs, oral SERDs, and treatment sequencing. They explore when and how to test f...
T-DXd Across HER2+ Breast Cancer with Drs. Paolo Tarantino & Seth Wander 06.10.2026 51:37
How is T-DXd reshaping the treatment pathway for HER2-positive breast cancer? Drs. Paolo Tarantino and Seth Wander discuss the rapidly evolving role of trastuzumab deruxtecan (T-DXd) across metastatic and early-stage HER2-positive breast cancer. From the first-line DESTINY-Breast09 data to the neoadjuvant DESTINY-Breast11 and adjuvant DESTINY-Breast05 data, they explore the new opportunities and c...
T-DXd in HER2+ Breast Cancer with Drs. Ruta Rao & Irene Kang 05.10.2026 38:50
How is T-DXd changing the treatment landscape for HER2-positive breast cancer? Drs. Ruta Rao and Irene Kang discuss the evolving role of trastuzumab deruxtecan (T-DXd) across HER2-positive breast cancer, from first-line metastatic disease to neoadjuvant and adjuvant treatment. They examine data from DESTINY-Breast09, DESTINY-Breast05, and DESTINY-Breast11, along with emerging maintenance strategie...
T-DXd Plus Pertuzumab in First-Line HER2+ Breast Cancer with Drs. Jason Mouabbi & Neil Iyengar 02.10.2026 45:51
How is DESTINY-Breast09 changing the first-line treatment landscape for metastatic HER2-positive breast cancer? Drs. Jason Mouabbi and Neil Iyengar discuss the evolving role of trastuzumab deruxtecan (T-DXd) plus pertuzumab in first-line metastatic HER2-positive breast cancer and how the DESTINY-Breast09 findings are influencing clinical decision-making. They examine how this approach compares wit...
Navigating First-Line CLL Treatment with Drs. Kerry Rogers, William Wierda & Catherine Coombs 29.09.2026 40:24
With more targeted therapies available for CLL, how are clinicians navigating the growing number of first-line treatment options? Drs. Kerry Rogers, William Wierda, and Catherine Coombs discuss the evolving CLL treatment landscape, including fixed-duration versus continuous therapy, BTK- and BCL-2 inhibitor–based approaches, and how disease biology, comorbidities, treatment logistics, and patient...
Evolving First-Line HER2+ Metastatic Breast Cancer with Drs. Sonya Reid & Shruti Singh 01.09.2026 29:15
For more than a decade, THP—established by the landmark CLEOPATRA trial— defined the first-line standard for HER2-positive metastatic breast cancer. Now, DESTINY-Breast09 is changing the conversation. In this CHM Conversation , Dr. Sonya Reid and Dr. Shruti Singh discuss the evolving first-line treatment landscape and how trastuzumab deruxtecan (T-DXd) plus pertuzumab is reshaping clinical decisio...
This Moment in Medicine: First-Line ADCs in Metastatic TNBC with Dr. Senthil Damodaran 13.08.2026 25:00
Are antibody-drug conjugates becoming the new first-line standard for metastatic triple-negative breast cancer? At This Moment in Medicine, hosted by Community Health Media, Dr. Senthil Damodaran reviews the latest data moving ADCs earlier in the treatment landscape for metastatic TNBC. The presentation focuses on TROPION-Breast02, ASCENT-03, and ASCENT-04, comparing datopotamab deruxtecan (Dato-D...
This Moment In Medicine: First-Line HER2+ Metastatic Breast Cancer with Dr. Mothaffar Rimawi 13.08.2026 21:29
How should we approach first-line treatment as the HER2-positive metastatic breast cancer landscape rapidly evolves? At This Moment in Medicine, hosted by Community Health Media, Dr. Mothaffar Rimawi examines how new data are reshaping a treatment landscape long defined by the CLEOPATRA regimen. From DESTINY-Breast09 to PATINA and HER2CLIMB-05, Dr. Rimawi explores emerging strategies for deeper HE...
This Moment in Medicine: T-DXd in Early HER2+ BC with Dr. Michelina Cairo 13.08.2026 24:34
Where should T-DXd fit in the treatment of high-risk, early-stage HER2-positive breast cancer? At This Moment in Medicine, hosted by Community Health Media, Dr. Michelina Cairo reviews the latest data from DESTINY-Breast11 and DESTINY-Breast05, examining how trastuzumab deruxtecan (T-DXd) could reshape treatment in both the neoadjuvant and adjuvant settings. From pathologic complete response and i...
This Moment in Medicine: Rethinking Adjuvant Therapy in ER+ Breast Cancer with Dr. Akshjot Puri 13.08.2026 27:42
How is adjuvant treatment for ER-positive, HER2-negative breast cancer changing? At This Moment in Medicine, Dr. Akshjot Puri examines key data from OPTIMA, lidERA, NATALEE, and monarchE—and what these trials could mean for chemotherapy de-escalation, endocrine therapy, ovarian suppression, and CDK4/6 inhibitor use. From using Prosigna to identify patients who may be able to avoid chemotherapy to...
Drs. Jason Mouabbi, Ruta Rao, & Mark Pegram - Unpacking DESTINY-Breast09 in HER2+ mBC 21.07.2026 54:57
A new era in HER2-positive metastatic breast cancer is here. Dr. Jason Mouabbi, Dr. Ruta Rao, and Dr. Mark Pegram break down the groundbreaking DESTINY-Breast09 trial and discuss how trastuzumab deruxtecan (T-DXd) plus pertuzumab is redefining first-line treatment. The conversation explores: Why DB09 may replace the CLEOPATRA standard The significance of 40+ month median PFS Complete response rate...
Dr. Anne O'Dea & Dr. Mabel Mardones - SERENA-6 & ctDNA-Guided Therapy in mBC 07.07.2026 32:12
Can we improve outcomes by changing treatment before radiographic progression occurs? In this in-depth discussion, Dr. Anne O'Dea and Dr. Mabel Mardones explore how the SERENA-6 trial is reshaping the management of HR-positive, HER2-negative metastatic breast cancer through ctDNA-guided treatment decisions and earlier intervention for emerging ESR1 mutations. Topics discussed include:The clini...
Dr. Rena Callahan & Dr. Aditya Bardia - Integrating T-DXd in HER2+ Breast Cancer: DB11, DB05 & DB09 26.06.2026 32:42
HER2-positive breast cancer treatment is evolving rapidly. With FDA approvals from DESTINY-Breast11 and DESTINY-Breast05, when should clinicians incorporate trastuzumab deruxtecan (T-DXd) into practice—and how should it be used across early-stage and into metastatic disease? In this in-depth discussion, Dr. Rena Callahan and Dr. Aditya Bardia explore how these landmark studies are changing treatme...
Dr. Neil Iyengar, Dr. Joyce O'Shaughnessy, & Dr. Ana Garrido-Castro - Evolving ADCs in 1L mTNBC 26.06.2026 38:32
The first-line treatment landscape for metastatic triple-negative breast cancer is changing rapidly. Dr. Neil Iyengar, Dr. Joyce O'Shaughnessy, and Dr. Ana Garrido-Castro discuss how ADCs are reshaping frontline TNBC care and what the latest clinical evidence means for real-world practice. The conversation explores:• The evolution of metastatic TNBC treatment• Why many patients never reach sec...
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.